Stocks Health care IMCR
NASDAQ · Health careImmunocore Holdings plc (IMCR)
Immunocore Holdings plc brought in $429.3M of revenue over the twelve months to September 30, 2026, up 13.1% from a year earlier. It posted a net loss of $32.1M. In fiscal 2025 capital spending exceeded operating cash flow by $15.1M. At September 30, 2026 it held $512.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 6, 2026.
Key facts about Immunocore Holdings plc
- Net worth
- Immunocore Holdings plc has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of $419.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $400M (+29.0% year on year), with a net loss of $35.5M. Over the 12 months to September 30, 2026: revenue $429.3M, net loss $32.1M.
- Cash flow
- In fiscal 2025 operations used $10.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 6, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Immunocore Holdings plc's next report is expected around January 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Immunocore Holdings plc does
Immunocore Holdings plc is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker IMCR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $400M | -$35.5M | -$0.71 | -$15.1M |
| 2024 | $310.2M | -$51.1M | -$1.02 | $20.9M |
| 2023 | $249.4M | -$55.3M | -$1.13 | -$2.5M |
| 2023 | $174.4M | -$52.5M | -$1.15 | -$51.4M |
| 2021 | $36.5M | -$180M | -$4.24 | -$144.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where IMCR ranks in Health care
Latest SEC filings
What Immunocore Holdings plc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Passive stake (5% or more) SCHEDULE 13G
- November 6, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 1.4% to $102.2M versus the same quarter last year; diluted EPS -$0.28 versus $0.00.
- November 6, 2026
- October 7, 2026Passive stake changed SCHEDULE 13G/A
- September 14, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 18% to $115.9M versus the same quarter last year; diluted EPS -$0.02 versus -$0.20.
- August 6, 2026
Insider trades
What the people running Immunocore Holdings plc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| February 18, 2026 | Jallal BahijaCHIEF EXECUTIVE OFFICER, Director | Sold | 11,474 | $371.2K |
| February 18, 2026 | Goll JohnSVP, FINANCE & CAO | Sold | 698 | $22.6K |
| February 18, 2026 | Berman David MHEAD OF R&D | Sold | 5,965 | $193K |
| February 18, 2026 | St Leger Tina AmberCHIEF HR OFFICER | Sold | 1,000 | $32.4K |
| February 17, 2026 | Jallal BahijaCHIEF EXECUTIVE OFFICER, Director | Exercised options | 23,817 | - |
| February 17, 2026 | Goll JohnSVP, FINANCE & CAO | Exercised options | 1,351 | - |
| February 17, 2026 | Berman David MHEAD OF R&D | Exercised options | 11,824 | - |
| February 17, 2026 | St Leger Tina AmberCHIEF HR OFFICER | Exercised options | 2,119 | - |
Who owns IMCR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Wellington Management Group LLP13G, passive with 3 related filers | 11.6% | August 13, 2026 |
| RTW Investments, LP13G, passive with 1 related filers | 9.7% | November 14, 2024 |
| Fmr LLC13G, passive with 1 related filers | 8.8% | August 6, 2026 |
| Jallal Bahija13G, passive | 8.2% | February 14, 2025 |
| Primecap Management Co13G, passive | 7.51% | August 14, 2025 |
| Bellevue Group AG13G, passive with 1 related filers | 5.6% | November 14, 2025 |
| Point72 Asset Management, L.P.13G, passive with 2 related filers | 5.2% | November 9, 2026 |
| Tang Capital Management, LLC13G, passive with 5 related filers | 5.2% | October 24, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 136 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Wellington Management Group Llp | 5,721,945 | +1,015,777 |
| Rtw Investments, LP | 4,869,798 | 0 |
| Fmr LLC | 4,307,246 | -521,908 |
| Primecap Management Co | 3,638,241 | -55,000 |
| Bellevue Group AG | 2,788,245 | -8,558 |
| Tang Capital Management LLC | 2,649,368 | 0 |
| Vestal Point Capital, LP | 1,800,000 | -966,868 |
| Two Sigma Investments, LP | 1,648,983 | +627,718 |
| Millennium Management LLC | 1,597,037 | +359,634 |
| Armistice Capital, LLC | 1,428,000 | +240,000 |
| Caligan Partners LP | 1,381,317 | new |
| Kynam Capital Management, LP | 1,375,000 | +490,063 |
| Bvf Inc | 1,294,463 | 0 |
| Trails Edge Capital Partners, LP | 1,063,234 | +380,637 |
| BlackRock, Inc. | 1,004,598 | +348,289 |
| Point72 Asset Management, L.P. | 990,280 | -111,991 |
| Jupiter Topco LLC | 709,022 | new |
| Cantor Fitzgerald, L. P. | 680,200 | +429,989 |
| Logos Global Management LP | 600,000 | -900,000 |
| Marshall Wace, Llp | 590,941 | +410,601 |
Insiders
4 insiders reported holding 19,974 shares in total, about $633.8K at the last price.
| Holder | Shares |
|---|---|
| Jallal BahijaCHIEF EXECUTIVE OFFICER, Director | 12,343 |
| Berman David MHEAD OF R&D | 5,859 |
| St Leger Tina AmberCHIEF HR OFFICER | 1,119 |
| Goll JohnSVP, FINANCE & CAO | 653 |
Questions about IMCR
What does Immunocore Holdings plc do?
Immunocore Holdings plc is a company in the Health care sector, listed on NASDAQ as IMCR. Its shares trade on NASDAQ under the ticker IMCR.
What is Immunocore Holdings plc's net worth?
Immunocore Holdings plc has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of $419.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Immunocore Holdings plc profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $32.1M on revenue of $429.3M.
How much revenue does Immunocore Holdings plc make?
Over the twelve months to September 30, 2026 Immunocore Holdings plc reported revenue of $429.3M. That is 13.1% more than a year earlier.
When did Immunocore Holdings plc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 6, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from November 9, 2026.
When is Immunocore Holdings plc's next earnings report?
Immunocore Holdings plc's next report is expected around January 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare IMCR with
Follow IMCR
Get an email when Immunocore Holdings plc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Immunocore Holdings plc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.